11 results on '"R. M. J. Ings"'
Search Results
2. Comparative biodisposition and metabolism of 14C-(+/-)-fenfluramine in mouse, rat, dog and man
- Author
-
N. C. Marchant, R. M. J. Ings, J. Williams, D. Wallace, M. Breen, A. R. Taylor, S. Bass, and D. B. Campbell
- Subjects
Male ,medicine.medical_specialty ,Fenfluramine ,Hydrochloride ,Health, Toxicology and Mutagenesis ,Metabolite ,Urine ,Biology ,Toxicology ,Biochemistry ,Excretion ,Rats, Sprague-Dawley ,chemistry.chemical_compound ,Feces ,Mice ,Dogs ,Species Specificity ,Norfenfluramine ,Internal medicine ,medicine ,Animals ,Humans ,Tissue Distribution ,Active metabolite ,Chromatography, High Pressure Liquid ,Pharmacology ,General Medicine ,Metabolism ,Rats ,Mice, Inbred C57BL ,Endocrinology ,chemistry ,Dealkylation ,Deamination ,Chromatography, Thin Layer ,medicine.drug - Abstract
1. The comparative metabolism of fenfluramine was investigated in mouse, rat, dog and man following a single oral dose of 14C-(+/-)-fenfluramine hydrochloride (1 mg/kg), and also in rat after eight consecutive 12-h subcutaneous doses (24 mg/kg). 2. Main route of excretion of radioactivity in all species and at all doses was into urine (80%), with only minor amounts of radioactivity found in faeces. 3. From all species examined a total of 11 metabolites were observed in urine and plasma by t.l.c. and h.p.l.c. analysis and no metabolite was present in the plasma which was not present in urine. 4. All species dealkylate fenfluramine to the active metabolite norfenfluramine, to a relative greater or lesser extent, with plasma metabolic ratios (norfenfluramine/fenfluramine) showing inter-animal variation (ratdogmouse = man). 5. These differences are due to the efficient deamination of both compounds to polar inactive metabolites in man, with less dealkylation and lower plasma levels of norfenfluramine compared with the other species studied. 6. In conclusion, major species differences in the metabolism of (+/-)-fenfluramine, both qualitative and quantitative were observed, and no one species had a similar metabolic profile to that found in man.
- Published
- 1992
3. Value of early pharmacodynamic and pharmacokinetic investigations with anticancer drugs: data from phase I tolerance studies on a new vinca alkaloid derivative
- Author
-
M. Clavel, P. Solere, D. Minaidis, S. Leyvraz, C. Ardiet, F. Lokiec, F. Turpin, E. Lelièvre, R. M. J. Ings, and C. Lucas
- Subjects
Adult ,Vinca ,Adolescent ,medicine.drug_class ,Health, Toxicology and Mutagenesis ,Pharmacology ,Toxicology ,Biochemistry ,Vinca alkaloid ,Bolus (medicine) ,Pharmacokinetics ,Neoplasms ,medicine ,Humans ,Vinca Alkaloids ,Aged ,biology ,Apocynaceae ,Dose-Response Relationship, Drug ,Chemistry ,Alkaloid ,General Medicine ,Middle Aged ,biology.organism_classification ,Antineoplastic Agents, Phytogenic ,Pharmacodynamics - Abstract
1. A novel anticancer vinca alkaloid derivative (I) has been given as an i.v. bolus to cancer patients, using four different dosage regimens with dose levels ranging from 0.04 to 0.84 mg/m2 (equivalent to between 0.12 and 1.35 mg per dose), and the pharmacokinetics determined up to 72 h after dosing. In addition, secondary effects of leukopenia and neutropenia, were related to drug exposure using a sigmoid Emax model. 2. Plasma levels of I declined in a triphasic manner with a terminal half-life of approximately 50 h; most drug elimination (55%) being associated with the terminal phase. 3. Clearance of I was relatively low (245 +/- 160 ml/min) and remained constant with increasing doses. Initial distribution volume was low (approximately 71) but once distribution was complete, it was comparatively high (327 +/- 2121). 4. Both leukopenia and neutropenia were fitted successfully to a sigmoid Emax model showing that these effects were related to the total exposure to the drug. The Hill constant was less than 1, indicating a relatively shallow exposure/response curve and a predictable, graded increase in response with increasing I exposure, rather than a sudden quantal response. 5. Pharmacokinetically, I shows some similarities to other vinca alkaloids in its plasma level decline profile, although there are some notable differences which can be exploited clinically. In addition, the ability to model both leukopenia and neutropenia to the exposure to I, provides a valuable tool in the design of the most appropriate dosage regimen for the drug, as well as for dose adjustment taking into account inter-individual variations.
- Published
- 1992
4. Interspecies scaling and comparisons in drug development and toxicokinetics
- Author
-
R. M. J. Ings
- Subjects
Pharmacology ,Drug ,Logarithm ,Metabolic Clearance Rate ,Health, Toxicology and Mutagenesis ,media_common.quotation_subject ,Extrapolation ,Drug Evaluation, Preclinical ,General Medicine ,Biology ,Toxicology ,Biochemistry ,Models, Biological ,Regression ,Xenobiotics ,Drug development ,Pharmacokinetics ,Species Specificity ,Toxicokinetics ,Animals ,Humans ,Allometry ,Biological system ,media_common - Abstract
1. Methods of interspecies extrapolation using physiological models and allometric scaling have been reviewed with their possible application to drug development, both for candidate drug selection and the interpretation of toxicokinetic data. 2. Physiological models offer a mechanistic approach to extrapolation from one species to another, examining individual components which interrelate to produce the characteristics of the whole system. Tissues of interest are arranged in anatomical order based on blood circulation, and the disposition of a drug can be simulated with knowledge of tissue size (volume), tissue perfusion (blood flow), drug permeability, binding of the drug between the tissue and blood (partition), as well as elimination. Using this approach the behaviour of the drug under different conditions, such as dose route, disease state or animal species, can be predicted. 3. The alternative approach of allometric scaling is an empirical examination of relationships between size, time and its consequences. A regression of the logarithm of the pharmacokinetic parameter and the logarithm of the body weight of the animal species produces a linear relationship which enables the value of pharmacokinetic parameters in any animal species to be calculated from the product of an allometric coefficient and the body weight to a power function. 4. Whilst this technique gives acceptable predictions for the pharmacokinetics of those drugs eliminated renally, or which are blood flow-dependent, there is poor prediction for humans for low clearance drugs primarily eliminated by the mixed-function oxidase system. This appears to be a result of differences in maturation, and can be corrected for by including a brain weight or maximum life-span potential term into the allometric equation. 5. Of the two approaches described for extrapolation of pharmacokinetics between animal species, physiological models tend to be resource-demanding and costly, with more frequent failures, but can be invaluable for examining target organ exposure and for the targeting of drugs as in cancer chemotherapy. For routine drug development, however, allometric scaling is potentially more useful since it uses data which are routinely obtained and the calculations are relatively simple. 6. The problems of intraspecies scaling from high-dose data to low-dose predictions are discussed with respect to current models of dose levels. A new approach is proposed using a modified Hill equation based on drug exposure, which should allow for a more meaningful determination of the toxicity of a compound with different drug exposures.(ABSTRACT TRUNCATED AT 400 WORDS)
- Published
- 1990
5. A New Method for the Measurement of Nitrosoureas in Plasma: an H.P.L.C. Procedure for the Measurement of Fotemustine Kinetics
- Author
-
A. J. Gray, B. H. Gordon, R. P. Richards, R. M. J. Ings, D. B. Campbell, and M. P. Hiley
- Subjects
Radioisotope Dilution Technique ,Nitrosourea ,Health, Toxicology and Mutagenesis ,Analytical chemistry ,Toxicology ,Biochemistry ,High-performance liquid chromatography ,Nitrosourea Compounds ,chemistry.chemical_compound ,Organophosphorus Compounds ,Pharmacokinetics ,Blood plasma ,medicine ,Animals ,Humans ,Carbon Radioisotopes ,Chromatography, High Pressure Liquid ,Pharmacology ,Chromatography ,Extraction (chemistry) ,General Medicine ,chemistry ,Fotemustine ,Sample collection ,Citric acid ,Half-Life ,medicine.drug - Abstract
1. An analytical method for a novel nitrosourea, fotemustine, has been developed using solid-phase extraction and h.p.l.c. with u.v. detection. As part of the development, different methods for stabilising fotemustine after sample collection have been investigated. The method has been successfully applied to pharmacokinetic studies in monkeys and man. 2. Providing plasma was separated immediately from blood and frozen within 3 min of collection, negligible degradation of fotemustine occurred. The samples could then be stored at -20 degrees C in the dark for up to six days particularly if thawing prior to analysis was accelerated using a 50 degrees C water-bath so that it was complete within 3 min. Equivalent results were also obtained with samples stabilised with 0.1 M citric acid immediately after the preparation of plasma. 3. The analytical method showed good precision with a within-day variation ranging between +/- 10.7% at the lowest concentration investigated (0.1 micrograms ml-1) to 2.0% at 50.0 micrograms ml-1. The accuracy of measurement was from 108.9% to 97.6% at 0.1 and 50.0 micrograms ml-1 respectively and the response was linear up to 50 micrograms ml-1. The minimum level of quantitation was 20 ng ml-1. 4. After a single intravenous bolus dose of [14C]fotemustine (100 mg m-2) to Cynomolgus monkeys, intact drug levels rapidly declined (t1/2 12.6 +/- 0.5 min) although the half-life of radioactivity (approx 100 h) was much longer. The plasma clearance of fotemustine was 225 +/- 63 ml min-1 with a volume of distribution based on area of 4.1 +/- 1.2 litres. 5. As with monkey, plasma levels of intact fotemustine in a patient given [14C]-drug as a 1 h constant rate intravenous infusion (approx. 100 mg m-2), declined rapidly but with a half-life of 23.2 min. Again, the half-life for total radioactivity was considerably longer (30.8 h). The plasma clearance was 1426 ml min-1 and the volume of distribution based on area was 47.71.
- Published
- 1989
6. The pharmacokinetics of oxpentifylline in man when administered by constant intravenous infusion
- Author
-
F. Nüdemberg, J. L. Burrows, R. M. J. Ings, and T. A. Bryce
- Subjects
Adult ,Male ,Pharmacology ,Metabolite ,General Medicine ,Oxpentifylline ,Plasma levels ,In Vitro Techniques ,Middle Aged ,Loading dose ,Pentoxifylline ,Kinetics ,chemistry.chemical_compound ,chemistry ,Pharmacokinetics ,medicine ,Humans ,Theobromine ,Infusions, Parenteral ,Pharmacology (medical) ,Steady state (chemistry) ,medicine.drug ,Whole blood - Abstract
Subjects were each given either a 25, 50 or 100 mg intravenous loading dose of oxpentifylline followed by an intravenous infusion at a constant rate of 1.5 mg/min for 3 h. Plasma levels of oxpentifylline were measured to obtain information on its pharmacokinetics and to establish which of the loading doses gave the most rapid attainment of the steady state plasma levels of intact drug. Oxpentifylline kinetics were best described by a two compartment model giving a characteristic dip in the plasma level versus time curves before steady state was reached when either the 50 or 100 mg loading doses, followed by the constant intravenous infusion, were given. The terminal half-life of oxpentifylline was 1.02 +/- 0.86 h, reflecting a very high clearance of the drug (approx. 3 000 to 6 000 ml/min). The high clearance could be attributed to extrahepatic metabolism occurring in blood which was observed in vitro using whole blood but not plasma. The clearance of a reduced metabolite of oxpentifylline was less than that of the intact drug, although the half-life was similar (0.83 +/- 0.18 h). Of the three loading doses tested, only the highest showed any side effects, these being transient and occurring within a 5 to 10 min period after dosing and appeared to correlate with the high initial plasma levels of the drug. The 25 mg loading dose gave initial plasma levels generally below the final steady state levels, whilst the 50 mg loading was the closest to giving immediate steady state plasma levels of oxpentifylline.
- Published
- 1982
7. Disposition of14C-loprazolam in animals and man
- Author
-
R. M. J. Ings, K. I. Johnson, J. M. Fromson, and H. P. A. Illing
- Subjects
Adult ,Male ,medicine.medical_specialty ,Health, Toxicology and Mutagenesis ,Absorption (skin) ,Toxicology ,Biochemistry ,Absorption ,Excretion ,Benzodiazepines ,Route of administration ,Dogs ,Oral administration ,Internal medicine ,medicine ,Animals ,Humans ,Tissue Distribution ,Intestinal Mucosa ,Uvea ,Enterohepatic circulation ,Feces ,Pharmacology ,Benzodiazepinones ,Chemistry ,Brain ,Rats, Inbred Strains ,General Medicine ,Metabolism ,Middle Aged ,Rats ,Kinetics ,Macaca fascicularis ,Endocrinology ,Anti-Anxiety Agents ,Liver ,Loprazolam ,medicine.drug - Abstract
The disposition of 14C-loprazolam has been studied in rat, dog, cynomolgus monkey and man using oral and parenteral dosing. In all species 14C was excreted principally in the faeces irrespective of the route of administration. In surgically prepared animals, 46% dose (rat) or 60% (dog) was excreted in bile and, together with urinary excretion, indicates that approx. two-thirds of an oral dose was absorbed. In rat there was relatively little enterohepatic circulation (approximately 26%) compared to dog (approximately 73%). Whole-body autoradiography and tissue-distribution studies in rat showed that 14C was distributed principally in liver and intestine, and was eliminated within 24 h. 14C was found in brain of rat and dog; in dog concn. levels were higher in white matter than in grey matter. In studies using pigmented animals, 14C was associated with the uveal tract of the eye and with other melanin-containing tissues. This was reversible and was eliminated from the eye of rat with a half-life of 3.4 d. Blood and plasma concn. of 14C and of unchanged loprazolam declined relatively rapidly in rat. In dog, cynomolgus monkey and man, total 14C concn. in blood fell more slowly than unchanged loprazolam. Less than 85% of loprazolam was protein bound in rat, dog or human plasma in vitro.
- Published
- 1983
8. The measurement of d-fenfluramine and its metabolite, d-norfenfluramine in plasma and urine with an application of the method to pharmacokinetic studies
- Author
-
R. M. J. Ings, L. J. King, B. H. Gordon, D. B. Campbell, and R. P. Richards
- Subjects
Adult ,Male ,Chromatography, Gas ,Fenfluramine ,Hydrochloride ,Health, Toxicology and Mutagenesis ,Metabolite ,Administration, Oral ,Urine ,Toxicology ,Biochemistry ,chemistry.chemical_compound ,Pharmacokinetics ,Oral administration ,medicine ,Humans ,Pharmacology ,Chromatography ,Norfenfluramine ,General Medicine ,Plasma ,Middle Aged ,chemistry ,Female ,Gas chromatography ,medicine.drug - Abstract
1. A specific and sensitive gas chromatographic assay is described for the measurement of d-fenfluramine and its de-ethylated metabolite, d-norfenfluramine, in biological fluids, together with some data on its application to the oral pharmacokinetics of the drug. 2. The analytical method developed has advantages over the previously described methods since it uses nitrogen specific detection and, when applied routinely, enables smaller sample volumes to be used (typically 1 ml of plasma) with a shorter chromatography time and an improved sensitivity (minimum quantifiable level of 2.5 ng ml-1). 3. Peak plasma concentrations of 22 and 24 ng ml-1 of intact drug were reached at 4 h after an oral dose of 14C-d-fenfluramine hydrochloride (30 mg) given to two volunteers as part of a metabolism and disposition study. Subsequently, concentrations of intact drug declined monoexponentially with a half-life of approximately 13 h. Peak concentrations of 10 and 8 ng ml-1 of the metabolite, d-norfenfluramine, were reached after 4 and 6 h and were maintained as a plateau for a further 4-6 h. Assessment of the half-life of the metabolite could not be made because of lack of data on the terminal portion of the curves. 4. The urinary excretion of d-fenfluramine (6.0 and 10.6% of the dose) and d-norfenfluramine (5.8 and 8.8% of the dose) was low, indicating extensive metabolism of the parent drug.
- Published
- 1989
9. Correlation of the clinical pharmacodynamics of loprazolam with serum concentration
- Author
-
J. McEwen, A. W. Pidgen, J. R. Lawrence, L. A. Stevens, C. D. Bevan, and R. M. J. Ings
- Subjects
Adult ,Male ,Health, Toxicology and Mutagenesis ,Pharmacology ,Toxicology ,Placebo ,Biochemistry ,Benzodiazepines ,Oral administration ,medicine ,Humans ,Hypnotics and Sedatives ,Dosing ,Benzodiazepinones ,biology ,business.industry ,Area under the curve ,General Medicine ,biology.organism_classification ,Crossover study ,Anti-Anxiety Agents ,Anesthesia ,Tasa ,Pharmacodynamics ,Female ,Loprazolam ,business ,Sleep ,medicine.drug ,Half-Life - Abstract
Six healthy fasted volunteers each received oral doses of a placebo, 1 mg and 2 mg loprazolam with one week between treatments using a double-blind balanced crossover design. Serum samples were obtained at selected times after dosing for measurement of loprazolam using a combined high-performance liquid and gas chromatographic assay. Drug effect was also measured at the corresponding times using self-assessment scales and psychomotor tests. The serum levels of loprazolam followed a somewhat irregular shape with secondary and tertiary peaks possibly associated with food intake. The maximum serum levels of loprazolam following 1 mg and 2 mg doses of the drug (6.0 +/- 2.6 and 11.3 +/- 2.9 ng/ml, respectively) occurred at approximately one hour after dosing. Both the maximum serum levels and the area under the curve of loprazolam measured to six hours increased in direct proportion to dose. Statistically significant drug effects were seen after 2 mg loprazolam, although the subjects also appeared sedated after 1 mg doses. There appeared to be a good correlation between the logarithm of the serum concentration of loprazolam and effect which suggested that the hypnotic activity of the drug was not mediated via a long-lived metabolite. A threshold serum concentration associated with evident sedation was observed at approximately 3 ng/ml.
- Published
- 1985
10. The fate of metronidazole and tis implications in chemotherapy
- Author
-
J. A. McFadzean, W. E. Ormerod, and R. M. J. Ings
- Subjects
Chromatography, Gas ,Health, Toxicology and Mutagenesis ,medicine.medical_treatment ,Physiology ,Administration, Oral ,Biological Availability ,Urine ,Biology ,Toxicology ,Hydroxylation ,Biochemistry ,Excretion ,Feces ,Drug Therapy ,Metronidazole ,medicine ,Animals ,Bile ,Clinical efficacy ,Pharmacology ,Chemotherapy ,Kidney ,General Medicine ,Rats ,medicine.anatomical_structure ,Intestinal Absorption ,Organ Specificity ,Immunology ,Injections, Intravenous ,Vagina ,Autoradiography ,Female ,Chromatography, Thin Layer ,Digestive System ,Oxidation-Reduction ,medicine.drug - Abstract
1. [14C]Metronidazole was rapidly absorbed from the gastro-intestinal tract of rats giving maximum blood levels of radioactivity, equivalent to 6-4 and 6-7 mug metronidazole per ml blood, 1 h after oral dosing. 2. There was rapid equilibration between blood and most tissues, although radioactivity was concentrated in the liver, kidney, gastro-intestinal tract and vaginal secretions. 3. The half-life of clearance of radioactivity from the majority of tissues was between 3 and 4 h, although it was longer in the skin (8 h) and gastro-intestinal tract (14 h). 4. Fourteen radioactive excretion products were detected in rat urine and all the major products were identified. These all contained a nitro group and represented 97 degrees of the total radioactivity excreted in urine. 5. Unchanged metronidazole was secreted throughout the entire length of the gastro-intestinal tract and into the vagina of rats. 6. A hypothesis has been proposed to explain the high clinical efficacy of metronidazole in treating trichomonal and amoebic infections.
- Published
- 1975
11. Characterisation of Glibenclamide Half-Life in Man: Acute Concentration-Effect Relationships
- Author
-
J. R. Lawrence, J. McEwen, R. M. J. Ings, A. W. Pidgen, S.E. Walker, and J.D. Robinson
- Subjects
Glibenclamide ,business.industry ,Medicine ,Concentration effect ,Half-life ,General Medicine ,Pharmacology ,business ,medicine.drug - Published
- 1982
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.